Citations

Showing 10 of 108094 citations.

INNV-01. DRAMATIC RESPONSE OF ERBB2 POSITIVE BRAIN METASTASES FROM LUNG ADENOCARCINOMA TO FAM-TRASTUZUMAB DERUXTECAN-NXKI
Thompson, Tracy, Luster, Sara, Sio, Terence, Westerlund, Lynsey, Ensign, Shannon P. Fortin , Mrugała, Maciej M. , Ensign, Shannon P. Fortin , Thompson, Tracy, Savvides, P.

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii141-vii141

10.1093/neuonc/noac209.541 Get It

Abstract BACKGROUND In May 2022 the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (FAM-TRAS) for adult patients with unresectable or metastatic Her-2 positive breast cancer who have received prior Her-2-based regimen and developed recurrence withing 6 months of completing therapy. Efficacy of the drug was established in the DESTINY-BreastO3 study. It has been suggested that fam-trastuzumab deruxtecan crosses blood-brain barrier, similarly to trastuzumab and another drug conjugate trastuzumab-DM1. CNS responses in patients with Her2 positive metastatic breast cancer have been reported. ERBB2 is a receptor tyrosine kinase from the family of EGFR/ERBB/HER family of kinases and its alterations can serve as a biomarker and actionable target in solid tumors. Here we present a case of CNS metastases from ERBB2 positive lung adenocarcinoma treated successfully with FAM-TRAS alone. METHODS Case report. RESULTS 50 y old man presented with a persistent cough. CT chest showed RUL nodule and peribronchial lymphadenopathy. Biopsy was positive for adenocarcinoma. Molecular testing has shown ERBB2 exon20 insertion, TP53 pathogenic variant, PDL1 positive (1%), and BRACA1 mutation. The patient had a solitary brain metastasis at the time of the initial diagnosis. He was started on FAM-TRAS and CNS response was seen while lung disease progressed. He was switched to immunotherapy but developed pneumonitis and therapy was stopped. He subsequently developed innumerable brain metastases and was restarted on FAM-TRAS. After 2 doses, dramatic response in CNS was seen with lung disease was stable. CONCLUSIONS This case demonstrates the critical importance of molecular testing in neuro-oncology in the era of novel systemic therapies, many with good blood-brain barrier penetration. Systemic therapies for brain metastases can be successfully implemented in the right clinical setting and they can allow for the deferral of radiotherapy. ERBB2 mutations can guide clinicians when choosing therapy for many solid tumors, including those with brain metastases.
IMMU-36. EVALUATION OF TUMOR DERIVED SERPINA3N IN EXPERIMENTAL GLIOBLASTOMA
Wolf, Delaney, Tritz, Zachariah P. , Hansen, Michael, Johnson, Aaron J. , Wolf, Delaney M. , Ayasoufi, Katayoun , Zheng, Jiaying , Jin, Fang , Johnson, Aaron

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii139-vii139

10.1093/neuonc/noac209.533 Get It

Abstract Glioblastoma (GBM) is an incurable brain cancer which is associated with severe peripheral immune suppression. Using experimental GBM, we recently determined that peripheral immunosuppression involves thymic atrophy, stunted T cell proliferation, and release of circulating factors that inhibit immune responses. RNA sequencing and proteomic studies have determined that transcripts and protein levels of Serpina3n are upregulated in the brain and serum of GBM patients and correlates with poor prognosis. We determined Serpina3n is a highly upregulated gene in the brain and the thymus of glioma-bearing mice using RNA sequencing technologies. Proteomic analysis of serum from glioma-bearing mice identified an upregulation of pathways associated with the extracellular expression of Serpina3n. We therefore sought to determine the role of Serpina3n in peripheral immunosuppression in GL261 glioma harboring wild type and Serpina3n knockout mice. Glioma implantation in Serpina3n knockout mice resulted in similar survival and peripheral immunosuppression compared to controls. Western blotting experiments confirmed that Serpina3n is expressed and secreted by GL261 gliomas isolated from WT and Serpina3n knockout mouse brains. Together this data suggests that tumor-derived, but not host derived, Serpina3n needs to be evaluated as a putative factor associated with peripheral immunosuppression.
IMMU-26. HEIGHTENED LEVELS OF CIRCULATING CELL-FREE DNA CONTRIBUTE TO PERIPHERAL IMMUNOSUPPRESSION DURING GBM PROGRESSION
Wolf, Delaney, Tritz, Zachariah P. , Gulbicki, Lauren , Hansen, Michael, Johnson, Aaron J. , Ayasoufi, Katayoun , Wolf, Delaney M. , Jin, Fang , Fain, Cori E. , Johnson, Aaron

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii136-vii137

10.1093/neuonc/noac209.523 Get It

Abstract Glioblastoma (GBM) is an incurable and aggressive form of brain cancer that is associated with severe peripheral immunosuppression. This immunosuppression is a critical barrier to patient survival and the success of immune modulatory therapies. Using the murine GL261 model of GBM, we recapitulated major features of peripheral immunosuppression observed in patients including T cell lymphopenia. We determined that peripheral immunosuppression in GBM is multifaceted and involves release of novel non-steroidal soluble factors with large molecular weight that are found in sera of glioma-bearing mice. These high molecular weight species potently inhibits T cell proliferation in vitro despite the presence of strong T cell stimulation. Our goal was to determine the identity of the immunosuppressive species in serum of glioma-bearing mice. We performed state-of-the-art comparative high throughput mass spectrometry on fractionated and multiplexed sera isolated from control and glioma-bearing mice. This proteomics analysis demonstrated histones as a top highly abundant protein in serum of glioma-bearing mice compared to naïve controls. Cell-free DNA has been recently identified as an immune suppressive factor in circulation and can be bound to histones. We, therefore, assessed cell-free DNA levels in the serum of glioma-bearing mice. We determined that sera isolated from glioma-bearing mice harbor significantly higher concentrations of double stranded and single stranded cell-free DNA compared to healthy controls. Reducing the DNA content in serum, using DNAse treatment, partially improved the defect in T cell proliferation observed when T cells are exposed to serum isolated from glioma-bearing mice. These data indicate that heighted levels of circulating DNA in serum contributes to peripheral immunosuppression in GBM. These findings provide a tractable approach to investigate the cellular source and immunosuppressive effects of cell-free DNA in murine models of GBM and to devise strategies to reverse immunosuppression with the hope of improving outcomes in patients.
DISP-14. DEFINING INTERVENTIONS AND METRICS TO IMPROVE DIVERSITY IN CNS CLINICAL TRIAL PARTICIPATION: A SNO AND RANO EFFORT
Porter, Alyx B. , Jackson, Sadhana , Lee, Eudocia Q. , Willmarth, Nicole E. , Dalmage, Mahalia , Arons, David, Chang, Susan M. , Wen, Patrick Y. , Hervey‐Jumper, Shawn L. , Chukwueke, Ugonma , Budhu, Joshua , McFaline-Figueroa, J Ricardo , Kawachi, Ichiro , Chang, Susan Marina , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii130-vii130

10.1093/neuonc/noac209.496 Get It

Abstract Despite major strides in cancer research, care, and therapy, these advances have not been equitable across race and ethnicity. Groups underrepresented in medicine (URM) are more likely to have inadequate preventive screening, increased delays in diagnosis, and poor representation in clinical trials. Notably, Black and Latino Americans represent 29% of the population but only reflect 8% of oncology clinical trial participants. Recent studies have shown that this disparity is also present in neuro-oncology as women, Black, and Latino Americans remain under-accrued in clinical trials. Brain tumor patients already face unique barriers to clinical trial enrollment and completion due to disease-specific conditions–such as impaired motor function, cognition, language deficits, and caregiver dependency–which pose additional difficulties in clinical trial consent, enrollment, and adherence. As part of this collaborative initiative, we evaluated the impact of how a lack of diversity in cancer research is detrimental to scientific discovery and propose interventions focused on improving URM engagement with clinical research. Recommendations include the creation of inclusive trial design at the onset, decreasing barriers to care, expanding trial eligibility, and equitable access to tumor profiling for personalized medical trials. Additionally, setting reasonable metrics and goals for accrual and engagement with patient and community stakeholders will ultimately help to diversify trial participants. Lastly, diversification and inclusion practices within the neuro-oncology workforce, including all personnel involved in clinical research, will help to minimize bias, promote concordant care, and assist with developing sustainable solutions. The diversification of participation in neuro-oncology clinical trials is imperative. The lack of diversity in clinical trials can contribute to improper generalizability of treatment efficacy, resulting in potentially harmful practices. Equitable access and inclusion of URM brain tumor patients will not only enhance research discoveries but will also result in improved patient care for all cancer patients.
EPCO-38. TYPE B ULTRA LONG-RANGE INTERACTIONS IN PFAS (TULIPS) ARE RECURRENT EPIGENOMIC FEATURES OF PFA EPENDYMOMA
Lee, John J. Y. , Chen, Carol, Balin, Polina , Fong, Vernon , Zwaig, Melissa , Billon, Pierre, Juretic, Nikoleta , Kim, Seung‐Ki , Wang, Kyu‐Chang , Ellezam, Benjamin , Majewski, Jacek , Johnston, Michael J.G. , Hu, Bo , Nikolić, Ana , Baguette, Audrey , Paik, Seungil , Chen, Haifen, Kumar, Sachin A. , Jessa, Selin , Michealraj, Kulandaimanuvel Antony , Chen, Xun , Zhang, Yanlin , Varadharajan, Srinidhi , Daniels, Craig, Giannini, Caterina , Thompson, Eric M. , Hauser, Péter , Lee, Ji Yeoun , Grajkowska, Wiesława , Agnihotri, Sameer , Mack, Stephen C. , Weil, Alexander G. , Bourque, Guillaume , Chan, Jennifer Ai-wen , Lupien, Mathieu , Ragoussis, Jiannis , Kleinman, Claudia L. , Jabado, Nada , Taylor, Michael D. , Blanchette, Mathieu , Gallo, Marco

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii124-vii124

10.1093/neuonc/noac209.472 Get It

Abstract Posterior Fossa Group A (PFA) ependymomas are pediatric brain tumors with extremely poor survival outcomes. As protein-coding mutations in PFA are exceedingly rare, the underlying etiology of these tumors remains elusive. Elevated CpG island methylation and depletion of H3K27me3 have been described in PFA, leading to the hypothesis that PFA may be driven by a dysregulated epigenetic state. In this study, we sought to determine how three-dimensional (3D) genome features (such as DNA loops, domains, and compartments) differ between pediatric brain tumors. We performed Hi-C sequencing on a collection of 64 patient specimens and patient-derived primary cultures that collectively span multiple subgroups of ependymoma, medulloblastoma, high-grade glioma, and non-neoplastic brain. For certain samples, we further performed RNA-seq, histone modification ChIP-seq, or whole-genome bisulfite sequencing to allow multiomic data integration. Overall, the 3D genome organization of PFA samples appeared distinct from other tumor types. We identified and defined TULIPs: a subset of type B compartments, separated by genomic distances greater than 10 Mbp, that exhibit a striking fivefold increase in reciprocal interaction strength. These TULIPs recurred at the same genomic positions across the vast majority of PFA samples with minimal representation among other tumor or non-tumor samples. TULIPs displayed enrichment for heterochromatic features such as H3K9me3 and late replication timing and were depleted of euchromatic features such as H3K27ac and protein-coding genes. By using immuno-fluorescence for H3K9me3 and oligo-FISH to label TULIP regions, we demonstrated that TULIP regions are more compact in PFA than other tumors. Finally, by applying inhibitors of H3K9 lysine methylation to PFA cultures we showed that TULIPs become more diffuse and cell viability is reduced. Altogether, this work defines TULIPs as highly recurrent epigenetic features of PFA tumors.
EPCO-12. SEX-SPECIFIC PATTERNS CONNECTING LOCOREGIONAL MRI FEATURES AND IMMUNOHISTOCHEMISTRY OF IMAGE-LOCALIZED BIOPSIES OF GLIOBLASTOMA
Langworthy, Jazlynn , Ranjbar, Sara , Singleton, Kyle , Boyett, Deborah , Canoll, Peter , Swanson, Kristin R. , Swanson, Kristin R , Jackson, Pamela , Hawkins‐Daarud, Andrea , Argenziano, Michael , Grinband, Jack

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii118-vii118

10.1093/neuonc/noac209.447 Get It

Abstract Glioblastoma (GBM) is the most aggressive primary brain tumor with a median survival of 14 months. GBMs are challenging to treat due to their heterogeneous nature. It has also been seen that these tumors have sex differences in their cellular subtypes as well as imaging. Radiomics has the potential to provide a non-invasive, spatial understanding of genetic and epigenetic diversity in these complex tumors and to aid in treatment planning. We have an ongoing study to obtain image-localized biopsies from GBM patients, allowing us to complete radiomic analysis and make connections between immunohistochemistry (IHC) and magnetic resonance imaging (MRI) features. We sought to determine if the patterns on imaging were correlated with underlying tumor biology. We focused on immunohistochemistry (IHC) markers of key features of tumor biology including SOX2 for stem-like tumor cells, CD68 for immune response and Ki67 for proliferation kinetics. Our study included 38 patients with a total of 99 biopsies (bxs): 27 males with 77 bxs and 11 females with 22 bxs. Biopsies were sectioned and stained for the SOX2, CD68, and KI67 markers. We computed 18 first-order radiomic features at each biopsy location for patients’ multimodal MRIs: T1W, T1Gd, T2W, FLAIR, apparent diffusion coefficient, diffusion weighted imaging (DWI) and susceptibility weighted imaging. We then performed correlation analysis between each radiomic feature and marker abundance for each IHC stain. Overall, we found sex-distinct patterns connecting imaging with these IHC markers. For example, amongst female patients, DWI held more prominent correlations with SOX2 than in males. Whereas there were more correlations between CD68 IHC abundance and T1Gd imaging features in males compared to females. Taken together, the overall patterns connecting locoregional imaging features to these IHC markers showed sex-distinct patterns suggesting the potential for sex to be an important biological variable when interpreting the biology underlying imaging changes.
EPCO-14. ISOSCELES: AN INTEGRATIVE FRAMEWORK FOR THE PREDICTION OF TREATMENT RESISTANT GLIOBLASTOMA CELLS
Jermakowicz, Anna, Stathias, Vasileios , Ruiz, Luz , Kaeppeli, Simon , Baker, Grace, Veeramachaneni, Rithvik, Walters, Winston, Cepero, Maria L., Williams, Siôn, Komotar, Ricardo J. , Fuente, Macarena de la, Schürer, Stephan C. , Ayad, Nagi , Suter, Robert K. , Jermakowicz, Anna M. , D’Antuono, Matthew , Ivan, Michael E , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii118-vii118

10.1093/neuonc/noac209.449 Get It

Abstract Glioblastoma (GBM) remains the most common and lethal adult primary brain cancer. Two of the most significant issues preventing the development of effective GBM treatments are inter- and intra-tumor heterogeneity. To address these issues, we developed a novel platform termed ISOSCELES (Inferred cell Sensitivity Operating on the integration of Single-Cell Expression and L1000 Expression Signatures). ISOSCELES integrates single-cell gene expression data in individual GBM tumors with perturbation-response data derived from the NIH Library of Integrated Network-Based Cellular Signatures (LINCS) L1000 dataset to predict sensitive and resistant tumor cell populations. Importantly, we analyzed the predictive power of ISOSCELES in an in vivo xenograft model and demonstrated that ISOSCELES reveals the GBM cell identities primed for lineage expansion during treatment with the aurora kinase inhibitor alisertib. These studies suggest that ISOSCELES can be used to identify sensitive and resistant cell populations to targeted therapies in GBM, which can inform treatment decisions in ongoing and future clinical trials.
EPCO-03. PATHWAY-BASED STRATIFICATION OF GLIOBLASTOMA BY MULTI-OMICS INFORMS SUBTYPE-SPECIFIC MASTER KINASES-PHOSPHOSITE SUBSTRATES
Migliozzi, Simona, Hasanain, Mohammad, Lasorella, Anna , Oh, Young Taek , Hasanain, Mohammad, Garofano, Luciano , D’Angelo, Fulvio , Pïcca, Alberto , Bielle, Franck , Sarkaria, Jann N. , Ceccarelli, Michele , Sanson, Marc , Iavarone, Antonio

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii116-vii116

10.1093/neuonc/noac209.438 Get It

Abstract Tumor heterogeneity and broad therapeutic resistance are major challenges when treating patients with glioblastoma (GBM). Moreover, different from other cancer types, the absence of clinically useful classifiers for glioblastoma has hampered the translation of genomic and proteomic information to improve diagnosis and design precision therapeutics for patients. We analyzed a large dataset of human GBM to determine the multi-omics features characterizing the four GBM subtypes that we have recently identified through single-cell RNA sequencing and validated in bulk tumor analysis. Each subtype exhibits activation of unique functional traits that confer distinct therapeutic vulnerabilities. The examination of proteomics, phosphoproteomics, metabolomics, lipidomics and acetylomics data revealed that each GBM subtype has a coherent molecular structure driving the dominant function traceable in each analytical platform. Functional classes are not a specific attribute of GBM as we identified the same subtypes in breast and lung cancer. To test the translational impact of proteomic data in GBM, we developed an unbiased protein kinase signaling network approach for the selection of master kinases (MKs) aberrantly activated in each GBM subtype. We identified therapeutically actionable MKs and novel phosphorylation substrates that we experimentally validated. To provide rapid translation of the functional classifier for precision medicine in GBM, we developed a probabilistic classification tool which determines the probability that a patient’s GBM belongs to one of the four subtypes, exhibiting optimal performance when using RNA extracted from either frozen and paraffin-embedded tissues. The algorithm is publicly accessible and can be used to evaluate the association of therapeutic response with GBM subtypes and as tool for selection criteria in prospective clinical trials.
EPID-17. CENTRAL NEUROCYTOMA: RESEARCH TRENDS, MOST CITED PAPERS, AND SCIENTOMETRICS ANALYSIS TO DATE
Durrani, Sulaman , Tebha, Sameer Saleem , Bydon, Mohamad , Qamar, Mohammad Aadil , Nathani, Karim Rizwan

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii113-vii113

10.1093/neuonc/noac209.427 Get It

Abstract INTRODUCTION Central neurocytoma is the most common primary intra-ventricular tumor in adults being classified by the World Health Organization (WHO) as a benign grade II tumor with a good prognosis. Given the recent advances with regards to this tumor, a bibliometric analysis was due to study the change in research interest and patterns to identify the future direction of research for neurocytomas. MATERIALS AND METHODS A comprehensive Elsevier’s Scopus database search was performed to capture all published and indexed studies to date using the keywords "neurocytoma" and "central neurocytoma". A discrete set of validated bibliometric parameters were extracted and analyzed. All statistical analyses were performed on R 4.1.2. RESULTS A total of 1,002 documents were included in our analysis covering a period between 1910-2021 (111 years). Around 98.5% of the documents were multi-author publications with a collaboration index (CI) of 4.21. Acta Neuropathologica, The American Journal of Surgical Pathology, and Cancer were the journals to include the most number of top ten cited articles (2 out of 10 most cited articles, 20%). Switzerland (4 out of 10, 40%) accounted for the country to have the most number of top 10 most cited articles. The United States of America (5588 out of 16395 citations, 34.1%) had the most number of citations. Lastly, our analysis reported an annual growth rate of 6.9% for the number of papers produced by year. CONCLUSION This is the first bibliometric analysis to study the top 10 most cited articles with regard to neurocytomas. A shift from histopathologic and clinical symptoms toward treatment and management of the tumor was observed in our analysis. These findings highlight the need for investigation into treatment modalities for future research.
DDDR-28. EGFR AND SRC-MEDIATED ACTIVATION OF STAT3 DRIVES RESISTANCE TO MITOTIC INHIBITORS IN GLIOBLASTOMA, AND CAN BE REVERSED WITH FDA-APPROVED DRUGS
Kenchappa, Rajappa S., Dovas, Athanassios, Pereira, Brianna , Griffith, Jessica I. , Mohammad, Afroz S., Elmquist, William F. , Quaranta, Vito , Canoll, Peter , Rosenfeld, Steven S. , Argenziano, Michael , Meyer, Christian T. , Stopfer, Lauren E. , Banu, Matei A. , Talele, Surabhi , Zarco, Natanael , White, Forest M. , Sims, Peter A.

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii105-vii105

10.1093/neuonc/noac209.393 Get It

Abstract While the allure of targeted therapies in oncology has been their high degree of specificity and potency for key tumor drivers, they have been disappointing in glioblastoma (GBM), even for drugs that are blood brain barrier permeable and CNS retained. This point is highlighted by the experience with mitotic spindle inhibitors, drugs which block the G2M transition and induce mitotic catastrophe—a phenotype characterized by cell enlargement and polyploidy that leads to apoptotic cell death. We have shown that one of these, a potent inhibitor of the mitotic kinesin Kif11 (ispinesib), is highly active against GBM tumor initiating cells and prolongs survival in murine models of this disease. However, tumors eventually progress, reflecting the development of drug resistance. Although ispinesib resistant GBM cells develop mitotic catastrophe, they become highly resistant to the apoptosis that typically follows and continue to proliferate. We find that this apoptosis resistance requires phosphorylation of the transcription factor STAT3 at two residues—Y705 and S727. Phosphorylation of Y705, mediated by SRC kinase, translocates STAT3 to the nucleus where it induces transcription of anti-apoptotic proteins. Phosphorylation at S727, mediated by EGFR, translocates STAT3 to the mitochondria where it blocks release of cytochrome c—the penultimate effector in apoptosis. Simultaneously inhibiting both SRC and EGFR with FDA-approved, CNS permeant inhibitors reverses this resistance and significantly prolongs survival in ispinesib-treated GBM-bearing mice. Furthermore, we find that resistance to several other mitotic inhibitors also utilizes this STAT3-driven mechanism and can likewise be reversed with combined EGFR and SRC inhibition. Thus, our work demonstrates how a promising therapeutic approach, which has been disappointing in GBM, can in fact be rendered effective by anticipating and prospectively treating ab initio the mechanism that drives treatment resistance.